Blake Borgeson, an insider of Recursion Pharmaceuticals, Inc. (RXRX), reported a sale of Class A common stock that took place on July 7, 2026. The Form 4 indicates that Borgeson sold 40,000 shares at a weighted-average price of $3.9625 per share, for an estimated total value of about $158,500. The reported transaction was a sale of Recursion Class A common stock and appears to be reported under transaction code “S,” the standard Form 4 code for an open-market or private sale. The shares were not sold in a single-price trade; the filing states the sale was executed in multiple trades at prices ranging from $3.95 to $4.00 per share. The $3.9625 figure represents the weighted-average sale price. Borgeson agreed to provide detailed price-by-price trade information upon request to the SEC staff, the company, or a Recursion security holder. The sale was made pursuant to a Rule 10b5-1 trading plan adopted by Borgeson on August 31, 2025. Such plans allow insiders to set predetermined trading instructions in advance, often to reduce concerns that trades are being made on the basis of material nonpublic information. The filing text provided does not state Borgeson’s beneficial ownership after the sale, so the remaining number of shares held following the transaction cannot be determined from the excerpt. The filing was signed on July 9, 2026, by Jonathan Golightly as attorney-in-fact for Borgeson.